Stocklytics Platform
Asset logo for symbol ZYME
Zymeworks
ZYME64
$12.54arrow_drop_up2.95%$0.36
Asset logo for symbol ZYME
ZYME64

$12.54

arrow_drop_up2.95%
Key Stats
Open$12.23
Prev. Close$12.18
EPS-1.50
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range12.20
12.67
52 Week Range6.01
13.14
Ratios
EPS-1.50
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.97%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

ZYME-
US Healthcare Sector-
US Market-
check_circle

ZYME / Market

ZYME exceeded the US Market which returned -0.14% over the last twenty four hours.
check_circle

ZYME / Healthcare Sector

ZYME exceeded the US Healthcare sector which returned 0.71% over the last twenty four hours.

Zymeworks (ZYME) Statistics

Zymeworks Inc (ZYME) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of multifunctional biotherapeutics. The company's lead product candidate, ZW25, is a bispecific antibody that targets HER2-positive cancers. ZW25 has shown promising results in early-phase clinical trials and has the potential to provide a significant improvement in treatment options for patients with HER2-positive breast and gastric cancers.
In terms of valuation metrics, Zymeworks Inc (ZYME) currently has a market capitalization of around $2 billion. The company's valuation is relatively high compared to its revenues, indicating high investor expectations for future growth. However, it is important to note that valuation metrics alone do not provide a complete picture of a company's value and should be interpreted in conjunction with other fundamental factors.
add Zymeworks  to watchlist

Keep an eye on Zymeworks

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Zymeworks (ZYME) stock's performance compared to its sector and the market over the past year?

Over the past year, Zymeworks (ZYME) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 22.23%, Zymeworks has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 61.01%, it has fallen short of the market average. This comparison highlights Zymeworks 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Zymeworks (ZYME) stock?

The PE ratio for Zymeworks (ZYME) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Zymeworks (ZYME) stock?

The Earnings Per Share (EPS) for Zymeworks (ZYME), calculated on a diluted basis, is -$1.5. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Zymeworks (ZYME) stock?

The operating margin for Zymeworks (ZYME) is -133.03%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Zymeworks (ZYME) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Zymeworks (ZYME) is -$115.55M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Zymeworks (ZYME) have?

Zymeworks (ZYME) has a total debt of $20.09M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$50.9M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media